| 49th week of 2009 patent applcation highlights part 44 |
| Patent application number | Title | Published |
|---|
| 20090297467 | COSMETIC COMPOSITION COMPRISING A SULPHONATED POLYMER AND AN ACRYLATE OR METHACRYLATE AND ACRYLATE OR METHACRYLATE HYDROXYESTER COPOLYMER, AND THE USE THEREOF AS A HAIR CARE PRODUCT - A subject-matter of the present invention is a cosmetic composition comprising, in a cosmetically acceptable medium:
| 2009-12-03 |
| 20090297468 | Mixtures Comprising Anthranilic Acid Amides and Cooling Agents as Cosmetic and Pharmaceutical Compositions for Alleviating Itching - The invention relates to a mixture comprising or consisting of:
| 2009-12-03 |
| 20090297469 | Cyanoacrylate Monomer Formulation Containing Diiodomethyl-p-tolylsulfone and 2,4,4'-Trichloro-2'-Hydroxydiphenyl Ether - A polymerizable antimicrobial formulation for forming a wound closure adhesive comprising cyanoacrylate monomer, diiodomethyl-p-tolylsulfone and a halogenated hydroxyl diphenyl ether; and a method for closing the approximated edges of a wound with a polymeric film that substantially inhibits the growth of microorganisms, where the polymeric film is formed by use of the polymerizable antimicrobial formulation. | 2009-12-03 |
| 20090297470 | REMEDIES FOR ISCHEMIA - The present invention relates to uses and methods of parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), for recruiting stem cells into tissue suffering from ischemia, wherein said stem cells are preferably capable of repairing and/or regenerating said tissue suffering from ischemia. Also provided is the use of a combination of G-CSF or a G-CSF fragment and a DPP IV inhibitor/antagonist in the medical intervention of an ischemic disorder. Accordingly, the uses and methods of the present invention are preferably suitable for the prevention and/or treatment of ischemia. Moreover, the present invention relates to a composition comprising parathyroid hormone (PTH), preferably PTH (1-34), and/or parathyroid hormone-related peptide (PTHrP), preferably PTHrP (1-34), and/or G-CSF or a G-CSF fragment for use as a pharmaceutical composition. In a particular aspect of the invention, a DPP IV antagonist is applied in the uses, methods and/or compositions of the present invention. The DPP IV antagonist/inhibitor is preferably used in combination with G-CSF or a G-CSF fragment. Also the use of PTH alone or PTHrP alone or in combination with a DPP IV antagonist as well as the one of a combination of G-CSF or a G-CSF fragment and a DPP IV inhibitor/antagonist in the herein disclosed medical and pharmaceutical uses and methods is part of this invention. | 2009-12-03 |
| 20090297471 | Methods For Autologous Stem Cell Transplantation - Materials and methods for obtaining populations of lymphocytes and administering the population of lymphocytes to a subject are disclosed herein. In particular, disclosed herein are materials and methods for obtaining lymphocyte populations that contain at least about 0.5×10 | 2009-12-03 |
| 20090297472 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors having the general formula | 2009-12-03 |
| 20090297473 | Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors - Compounds of a certain formula 1, | 2009-12-03 |
| 20090297474 | Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels - The present invention relates to a method for identifying patients who are likely to develop sepsis in response to infection, a method for monitoring the progress of sepsis in a patient and to an assay kit for identifying patients who are likely to develop sepsis and/or monitoring the progress of sepsis. | 2009-12-03 |
| 20090297475 | CYSTEINE DIOXYGENASE POLYMORPHISMS - The invention relates to the detection and identification of polymorphisms in cysteine dioxygenase (CDO) for the use of that diagnosis to identify a propensity in a patient towards rheumatoid arthritis and/or to have side effects with a number of drugs, to nucleic acid and isolated proteins encoding the polymorphisms, to assays for CDO activity and for the identification of compounds affecting CDO activity, and additionally to use of interferon-γ optionally in combination with different compounds, to treat rheumatoid arthritis. | 2009-12-03 |
| 20090297476 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 2009-12-03 |
| 20090297477 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders - The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these ThI-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post | 2009-12-03 |
| 20090297478 | Methods and Compositions for the Treatment of Lupus Using Clofarabine - This invention relates to methods of treating or preventing lupus comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate or clathrate thereof to a patient in need of such treatment. The invention further relates to methods of treating or preventing lupus comprising the administration of clofarabine or a pharmaceutically acceptable salt, hydrate, solvate or clathrate thereof and an additional therapeutic agent to a patient in need of such treatment. | 2009-12-03 |
| 20090297479 | DC-HIL CONJUGATES FOR TREATMENT OF T-CELL DISORDERS - The present invention relates to the use of DC-HIL and fragments and variants thereof to selectively target toxins to activated T-cells expressing a unique form of syndecan-4 that is not found on other cells. Thus, the toxin is delivered only to activated T-cells, and not to other syndecan-4 expressing cells. Such toxin-DC-HIL conjugates are useful in the treatment of T-cell inflammatory disorders such as dermatitis, autoimmune disease, and graft rejection, as well as T-cell lymphomas. | 2009-12-03 |
| 20090297480 | TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided. | 2009-12-03 |
| 20090297481 | ANIMAL FEED SUPPLEMENTS AND USES THEREOF - Described feed supplement compositions containing beneficial viable microorganisms and potentially other beneficial nonviable materials, and methods of use thereof. | 2009-12-03 |
| 20090297482 | PROBIOTIC STRAIN AND ANTIMICROBIAL PEPTIDE DERIVED THEREFROM - The invention relates to a strain of | 2009-12-03 |
| 20090297483 | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof - Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products. | 2009-12-03 |
| 20090297484 | METHOD FOR CURING AND PREVENTING ACQUIRED IMMUNE DEFICIENCY SYNDROME BY ALTERING CELL-SURFACE RECEPTORS IN PRECURSOR T-HELPER CELLS AND MATURE T-HELPER CELLS TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS VIRIONS ACCESS TO MATURE HELPER CELLS - The medical method by which a modified Human Immunodeficiency Virus or virus-like structure is used as a transport medium to carry a medically therapeutic ribonucleic acid to precursor T-Helper cells and mature T-Helper cells to prevent AIDS. The modified Human Immunodeficiency Virus or virus-like structures make contact with precursor T-Helper cells or mature T-Helper cells by means exterior probes. Once the exterior probes engage the precursor T-Helper cells' or mature T-Helper cells' cell-surface receptors, the modified virus or virus-like structures inserts into the cells the medically therapeutic ribonucleic acid they are carrying. The medically therapeutic ribonucleic acid causes T-Helper cells to express an altered cell-surface receptor on their surface thus thwarting HIV virions from being able to gain access to such cells, thus preventing AIDS. | 2009-12-03 |
| 20090297485 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS - Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue. | 2009-12-03 |
| 20090297486 | Survival, Differentiation and Structural Integration Of Human Neural Stem Cells Grafted Into the Adult Rat Spinal Cord - The present invention provides methods and compositions for treating spinal cord diseases and injuries. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue. | 2009-12-03 |
| 20090297487 | METHOD FOR INTRODUCING SIRNA INTO CELLS BY PHOTOCHEMICAL INTERNALISATION - The present invention relates to a method for introducing an siRNA molecule into the cytosol of a cell, said method comprising i) contacting said cell with an siRNA molecule, a carrier and a photosensiting agent, and ii) irradiating the cell with light of a wavelength effective to activate the photosensitising agent, wherein said carrier comprises a cationic polyamine such as a lipopolyamine in a non-liposomal formulation, polyethyleneimine (PEI), a betacyclodextrin amine polymer, an amine group containing dendrimer, and a cationic peptide. Cells or a population of cells obtainable by the method, a composition containing an siRNA molecule and the carrier molecule, kits and therapeutic uses of the above are also provided. | 2009-12-03 |
| 20090297488 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF PERIPHERAL VASCULAR DISEASE AND RELATED DISORDERS - Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 2009-12-03 |
| 20090297489 | Method for Expansion of Tumour-Reactive T-Lymphocytes for Immunotherapy of Patients with Cancer - The present invention discloses an improved method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes, which may be used for treating and/or preventing cancer. The method provides high numbers of tumour-reactive T-lymphocytes within a short time span and the possibility of directing development of tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes towards specific subpopulations. The method comprises a first phase of stimulating tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes with tumour-derived antigen together with at least one substance having agonistic activity towards the IL-2 receptor to promote survival of tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes; and a second phase of activating and promoting growth of tumour-reactive CD4+ T helper and/or CD8+ T-lympho-cytes, wherein the second phase is initiated when the CD25 cell surface marker (or IL-2R marker) is down-regulated on CD4+ T helper and/or CD8+ T-lymphocytes. | 2009-12-03 |
| 20090297490 | NOVEL HUMAN T-CELL POPULATION - The present invention has objects to provide a novel human T-cell population having both cytotoxic and immunosuppressive activities, and to a method for preparing the same. The above objects are attained by providing a human T-cell population which is obtainable by coculturing mononuclear cells, collected from human blood, with stroma cells and which has the following features:
| 2009-12-03 |
| 20090297491 | Compositions containing non-polar compounds - Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives. | 2009-12-03 |
| 20090297492 | Method for Improving Cognitive Performance - The present invention provides a method for improving cognitive performance that encompasses all of: sense; perception; recognition; judgment; and action or suppression; and is based on a higher brain function. The method for improving cognitive performance of the present invention includes administering astaxanthin and/or an ester thereof to an individual. The cognitive performance is, for example, at least one selected from the group consisting of judging ability, spatial attention-allocating ability, concentration on the recognition of surroundings, and agility as determined by speed and/or accuracy of a body reaction which requires a higher brain function. | 2009-12-03 |
| 20090297493 | NANOPOROUS PARTICLE WITH A RETAINED TARGET - Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest, which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the marker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target. | 2009-12-03 |
| 20090297494 | Diagnostic and treatment of a mental disorder - The present invention generally relates to the field of neurological, physiological and psychotic dysfunctions associated with a mental disorder such as schizophrenia, or a predisposition therefor. The invention further relates to genes and proteins, which, when varied in their normal expression, their nucleic acid sequence or in their activity, are associated with the mental disorder. Accordingly, the present invention relates to methods for diagnosis and to methods for prevention and/or treatment of a mental disorder. The present invention additionally relates to compositions for use in diagnosis and to kits for diagnosis of a mental disorder. The invention also relates to the use of a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention and to a pharmaceutical composition for use in prevention and/or treatment of a mental disorder. Further, the invention relates to methods for screening for a modulator of a mental disorder. More particularly, the present invention relates to methods, compositions and kits, a microarray and reagents for determining the presence of at least one polymorphism and/or at least one combination of polymorphisms of at least one copy of a gene involved in regulating the intracellular glutathione (GSH) level and/or GSH-oxidative stress-related gene expression in a human being. Further, the invention relates to a pharmaceutical composition for use in the treatment and/or prevention of a mental disorder, to the use of an active ingredient such as a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention of a mental disorder in patients with specific polymorphisms in genes involved in regulating the intracellular GSH level and/or GSH-oxidative stress-related gene expression. The invention also relates to methods of preventing and/or treating a mental disorder comprising administering a medicament to patients having said polymorphisms and to methods of screening for a modulator of a mental disorder. | 2009-12-03 |
| 20090297495 | HYDROLASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR IMPROVING PAPER STRENGTH - The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds). In another aspect, the invention provides methods for hydrolyzing steryl esters and triglycerides (e.g., in a paper pulp), into sterols, glycerol and free fatty acids, using enzyme(s) of the invention. The invention provides enzymes and methods for decreasing the amount of lipophilic extracts (“pitch”) in a pulp-comprising composition. The polypeptides of the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts, including the manufacture of cosmetics and nutraceuticals. | 2009-12-03 |
| 20090297496 | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases - The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome, | 2009-12-03 |
| 20090297497 | Methods and compositions for treating nephrogenic diabetes and insipidus - Disclosed are compositions and methods for treating nephrogenic diabetes insipidus and for induction of diuretic effect. | 2009-12-03 |
| 20090297498 | Milk Fat Globule Epidermal Growth Factor-Factor VIII And Sepsis - Provided are methods of treating a mammal undergoing sepsis or at risk for sepsis. Also provided are methods of preventing or treating a physiologic effect of sepsis in a mammal. Additionally provided is the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the treatment of a mammal having sepsis or at risk for sepsis. | 2009-12-03 |
| 20090297499 | USE OF CHARCOAL FOR TREATING INFLAMMATORY CONDITIONS - The invention relates to the use of charcoal in the manufacture of an oral composition for the treatment of an inflammatory condition other than an inflammatory bowel disease and other than interstitial or other inflammation within the kidney. | 2009-12-03 |
| 20090297500 | NON-SMALL CELL LUNG CANCER-RELATED GENE, ANLN, AND ITS INTERACTION WITH RhoA - The present invention provides compositions and methods for identifying compounds for treating cancer as well as methods for predicting a prognosis of cancer. In particular, the present invention provides methods and kits for identifying inhibitors of the interaction between ANLN and RhoA which find utility in the treatment and prevention of cancer, particularly lung cancers such as non-small cell lung cancer (NSCLC). Also disclosed herein are compositions for treating or preventing cancer identified by the screening method of the present invention and methods of using same in the treatment and prevention of cancer. | 2009-12-03 |
| 20090297501 | Structural Isomers of sc(Fv)2 - Structural isomers in sc(Fv)2 compositions of anti-human Mpl antibody and humanized anti-human Mpl antibody were separated, and the obtained structural isomers were cleaved at their linkers to confirm that the structural isomers are of single chain diabody type and bivalent scFv type. In addition, the agonistic activities of these structural isomers were revealed to be significantly different. Furthermore, the present inventors discovered that the content ratio of the structural isomers in sc(Fv)2 compositions could be regulated by altering temperature, modifying lengths of the linkers of sc(Fv)2, or amino acids in their variable regions. | 2009-12-03 |
| 20090297502 | CCR2 ANTAGONISTS FOR CHRONIC ORGAN TRANSPLANTATION REJECTION - Anti-chemokine monoclonal antibody therapy is provided for the prevention, control or reversal of chronic rejection mediated vascular remodeling, including, e.g., but not limited to MCP-1/CCR2 antagonist antibody therapy for the modulation of cardiovascular pathologies associated with cardiac graft rejection including intimal thickening, arteritis, fibrosis, and necrosis. | 2009-12-03 |
| 20090297503 | Blood Coagulation Factor VIII Activation-Enhancing Antibodies - For the first time, the present invention provides antibodies that enhance the generation of activated blood coagulation factor VIII. The antibodies enhance the cleavage of blood coagulation factor VIII at the Arg of position 372 and suppress the cleavage at the Arg of position 336 by recognizing and binding to the A2 domain of blood coagulation Factor VIII. Such antibodies are expected to be useful in preventing or treating diseases that develop or progress due to decrease or loss of the blood coagulation factor VIII activity, for example, hemophilia A, acquired hemophilia, and von Willebrand's disease. | 2009-12-03 |
| 20090297504 | BCMA POLYPEPTIDES AND USES THEREOF - The present invention relates to polypeptides that inhibit APRIL and/or BAFF binding to BCMA, nucleic acid molecules encoding the polypeptides, and compositions comprising the polypeptides. The present invention also relates to methods for treating an immune-related disease or cancer using the polypeptides and compositions of the invention. The present invention also relates to methods for identifying inhibitors of APRIL/BAFF binding to BCMA and APRIL/BAFF signaling. | 2009-12-03 |
| 20090297505 | ABETA BINDING MOLECULES - The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarily determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease. Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. | 2009-12-03 |
| 20090297506 | Classification of cancer - The invention discloses a method for classification of cancer in an individual having contracted cancer. The method of classification involves the determination of microsatellite status and a prognostic marker by examining gene expression patterns. The invention also relates to various methods of treatment of cancer. Additionally, the present invention concerns a pharmaceutical composition for treatment of cancer and uses of the present invention. The invention also relates to an assay for classification of cancer. | 2009-12-03 |
| 20090297507 | ADAM10 in Cancer Diagnosis, Detection and Treatment - This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the ADAM10 gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the ADAM10 gene. | 2009-12-03 |
| 20090297508 | Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction - The present invention provides a method for screening compounds to identify therapeutic candidates for treating hemostasis disorders, the method includes the steps of contacting a cell that expresses a CLEC-2 receptor with a test compound and a CLEC-2 receptor ligand, under conditions which, but for the presence of the test compound, permit binding of the CLEC-2 receptor to the CLEC-2 receptor ligand; and detecting if any increase or decrease in an indicator of CLEC-2 receptor activity is observed in comparison to a control; wherein an increase or decrease in the indicator in comparison to the control indicates that the test compound is a candidate for modulating hemostasis. | 2009-12-03 |
| 20090297509 | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases - A method to inhibit the growth of tumors in human patients, comprising treating the human patients with an effective amount of a combination of radiation and a non-radiolabeled protein receptor tyrosine kinase inhibitor, the overexpression of which can lead to tumorigenesis. | 2009-12-03 |
| 20090297510 | INHIBITION OF CALPAIN REDUCES ALLERGIC INFLAMMATION - The present invention provides for the use of a calpain inhibitor for the treatment of allergy diseases, inflammatory diseases and autoimmune diseases. In particular, it has been found that inhibition of calpain within mast cells decreases the release of chemical mediators into the surrounding environment, resulting in a decreased local inflammatory response. The present invention also provides for a method of decreasing IgE-dependent mast cell degranulation, mast cell mediator release and cytokine production in mast cells, comprising the step of administering to the mast cells an effective amount of a calpain inhibitor. | 2009-12-03 |
| 20090297511 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto. | 2009-12-03 |
| 20090297512 | COMPOSITIONS AND METHODS FOR MODULATING VASCULAR DEVELOPMENT - The present invention provides methods of using EGFL7 antagonist to modulate vascular development. Also provided herein are methods of screening for modulators of EGFL7 activity. Furthermore, methods of treatment using EGFL7 antagonists are provided. | 2009-12-03 |
| 20090297513 | ANTIBODIES TO IL-6 AND USE THEREOF - The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V | 2009-12-03 |
| 20090297514 | HUMANIZATION OF ANTIBODIES - The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention. | 2009-12-03 |
| 20090297515 | Use of Caspase-8 Inhibitors for Modulating Hematopoiesis - A method of inhibiting hematopoiesis in a subject is provided. The method is effected by downregulating an expression or activity of caspase-8 in the subject thereby inhibiting hematopoiesis therein. | 2009-12-03 |
| 20090297516 | ENGINEERED LECTINS FOR VIRAL INACTIVATION - Engineered lectins and methods of using such reagents for both preventing and treating a broad array of viral infections are provided. The lectins of the invention are engineered in two ways, first through the enhancement of the natural mode of action of lectins against viruses through linked multimerization, and second through the creation of a new class of reagents, hereinafter referred to as a “lectibody” or “lectibodies”, that engage host immune function in addition to simply binding glycosylated viral proteins via the combination of a lectin and the Fc region of an antibody in order to drive Fc-mediated effector functions including ADCC (antibody-dependent cell-mediated cytotoxicity), increased half-life, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) in response to a lectin-mediated carbohydrate-binding event. | 2009-12-03 |
| 20090297517 | METHODS FOR TREATING IL-18 MEDIATED DISORDERS - The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-18 by administering an IL-18 antagonist, such as soluble IL-18 receptor, a soluble IL-18 binding protein and/or an antibody. | 2009-12-03 |
| 20090297518 | IMMUNOPOTENTIATIVE COMPOSITION - Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection. | 2009-12-03 |
| 20090297519 | ANTINEOPLASTIC COMBINATIONS WITH mTOR INHIBITOR, TRASTUZUMAB, AND/OR HKI-272 - A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described. | 2009-12-03 |
| 20090297520 | Methods of using conjugated toxin peptide therapeutic agents - Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed. | 2009-12-03 |
| 20090297521 | CD33-SPECIFIC SINGLE-CHAIN IMMUNOTOXIN AND METHODS OF USE - A single-chain immunotoxin composition and method of treatment with the composition is disclosed. Preferably, the immunotoxin is comprised of a CD33-specific single chain Fv antibody fragment and a genetically engineered variant of | 2009-12-03 |
| 20090297522 | RECOMBINANT HUMAN EPO-FC FUSION PROTEINS WITH PROLONGED HALF-LIFE AND ENHANCED ERYTHROPOIETIC ACTIVITY IN VIVO - A recombinant fusion protein comprising a human erythropoietin peptide portion linked to an immunoglobulin peptide portion is described. The fusion protein has a prolonged half-life in vivo in comparison to naturally occurring or recombinant native human erythropoietin. In one embodiment of the invention the protein has a half-life in vivo at least three fold higher than native human erythropoietin. The fusion protein also exhibits enhanced erythropoietic bioactivity in comparison to native human erythropoietin. In one embodiment, the fusion protein comprises the complete peptide sequence of a human erythropoietin (EPO) molecule and the peptide sequence of an Fc fragment of human immunoglobulin IgG1. The Fc fragment in the fusion protein includes the hinge region, CH2 and CH3 domains of human immunoglobulin IgG1. The EPO molecule may be linked directly to the Fc fragment to avoid extraneous peptide linkers and lessen the risk of an immunogenic response when administered in vivo. In one embodiment the hinge region is a human Fc fragment variant having a non-cysteine residue at amino acid 6. The invention also relates to nucleic acid and amino acid sequences encoding the fusion protein and transfected cell lines and methods for producing the fusion protein. The invention further includes pharmaceutical compositions comprising the fusion protein and methods of using the fusion protein and/or the pharmaceutical compositions, for example to stimulate erythropoiesis in subjects in need of therapy. | 2009-12-03 |
| 20090297523 | Erm family binding agents and their use in diagnosis and treatment of proliferative conditions - The methods and compositions of the invention provide new diagnostic markers for cancers (e.g., ovarian cancer, PPC, etc.) and other proliferative diseases or conditions such as psoriasis and endometriosis. The methods and compositions of the invention further provide new treatments for such proliferative diseases or conditions. | 2009-12-03 |
| 20090297524 | Compositions monovalent for CD40L binding and methods of use - The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual. | 2009-12-03 |
| 20090297525 | Compositions, kits and methods for identification, assessment, prevention and therapy of cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 2009-12-03 |
| 20090297526 | Membranolytic Polypeptides and Methods of Use - The present invention includes polypeptides, polynucleotides encoding the polypeptides, antibodies to the polypeptides, and methods for using the polypeptides and antibodies. The polypeptides include those with at least 80% identity to | 2009-12-03 |
| 20090297527 | Binding Domains of Proteins of the Repulsive Guidance Molecule (RGM) Protein Family and Functional Fragments Thereof, and Their Use - The invention concerns the identification and use of neogenin receptor-binding domains of members of the repulsive guidance molecule (RGM) protein family as well as polypeptide fragments derived therefrom. The inventive domains, i.e. peptide fragments are suited as agents for the active or passive immunization of individuals as well as diagnostic and therapeutic agents for use with diseases or pathological conditions in whose origin or progression, a member of the RGM family and a cellular receptor assigned to this molecule are involved. The invention also concerns monoclonal and polyclonal antibodies directed against the inventive binding domains and against the polypeptides derived therefrom, and to method for producing the inventive domains, polypeptides and antibodies. | 2009-12-03 |
| 20090297528 | Methods to identify compounds useful for the treatment of proliferative and differentiative disorders - The present invention relates to the discovery, identification and characterization of nucleotide sequences that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host-cell expression systems and proteins encoded by the nucleotides of the novel substrate-targeting subunits. The present invention relates to screening assays that use novel and known substrate-targeting subunits of ubiquitin ligases to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel and known ubiquitin ligases which modulate activity of the novel and known ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative and differentiative disorders. | 2009-12-03 |
| 20090297529 | ANTI-FLT3 ANTIBODIES - The present invention provides fully human antibodies that specifically bind to human FLT3 within extracellular domains 4 or 5 with high affinity. The invention further provides methods of treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate. | 2009-12-03 |
| 20090297530 | HERV-K ANTIGENS, ANTIBODIES, AND METHODS - Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K | 2009-12-03 |
| 20090297531 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2009-12-03 |
| 20090297532 | Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor - The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF. | 2009-12-03 |
| 20090297533 | CONTROLLED RELEASE IMMUNOMODULATOR COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s). | 2009-12-03 |
| 20090297534 | Catalytic Immunoglobulins BBK32 and Uses Therefor - The present invention describes the composition of class and subclass selected pooled human immunoglobulins with catalytic activity, methods of preparation thereof, and therapeutic utility thereof. | 2009-12-03 |
| 20090297535 | Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling - The present invention relates to amino acid sequences that are directed against interleukin-6 (IL-6), as well as to compounds or constructs, and in particular proteins and polypeptides that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences, polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes. | 2009-12-03 |
| 20090297536 | Compositions, kits, and methods for identification, assessment, prevention and therapy of cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 2009-12-03 |
| 20090297537 | Combination therapy for the treatment of obesity and diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level - The present invention concerns combination of an amount of a BRS-3 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the BRS-3 agonist alone and by the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing obesity and diabetes and conditions related thereto and conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues. | 2009-12-03 |
| 20090297538 | NEUROTOXIC OLIGOMERS - This invention relates to methods and compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the invention relates to methods and compositions for the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect the invention provides a method of prophylaxis, treatment or alleviation of a condition characterized by pathological aggregation and accumulation of a specific protein associated with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed. | 2009-12-03 |
| 20090297539 | PROCESS FOR PRODUCTION OF REGULATORY T CELL - The present invention provides a method of producing a regulatory T cell, which includes culturing a peripheral CD25 | 2009-12-03 |
| 20090297540 | Induction of Indoleamine 2,3-Dioxygenase in Dendritic Cells by TLR Ligands and Uses thereof - The induction of indoleamine 2,3-dioxygenase (IDO) in an IDO-competent subset of dendritic cells by TLR ligands, including TLR9 ligands, and various uses thereof are presented. | 2009-12-03 |
| 20090297541 | MATURATION OF DENDRITIC CELLS - The invention relates to immunotherapy using dendritic cells (DCs). More specifically, it relates to methods for the maturation of DCs, a mature DC population and clinical uses thereof. Provided is a method for the ex vivo maturation of DCs, comprising providing immature DCs and contacting the immature DCs with an effective concentration of a non-toxic TLR4 agonist, such as Monophosphoryl lipid A (MPLA) or Diphosphoryl lipid A (DPLA), and an interferon gamma (IFNg) receptor agonist, under culture conditions suitable for maturation of the immature DCs to form a mature DC population. Also provided is an isolated population of mature DCs, preferably human mature DCs, and the use thereof in immunotherapy. | 2009-12-03 |
| 20090297542 | Adp-ribosylating toxin from listeria monocytogenes - An ADP-ribosylating toxin from | 2009-12-03 |
| 20090297543 | Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof - The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML). | 2009-12-03 |
| 20090297544 | NOVEL TUMOR ANTIGEN PROTEIN SART-3 AND TUMOR ANTIGEN PEPTIDES THEREOF - A novel tumor antigen protein and gene therefor, tumor antigen peptides derived from said tumor antigen protein or derivatives thereof as well as medicaments, prophylactics, or diagnostics for tumors using such tumor substances in vitro or in vitro are provided. | 2009-12-03 |
| 20090297545 | IMMUNOMODULATORY DAIRY PEPTIDES AND USES THEREOF - The present invention provide a new method for modulating the immune system of a subject in need thereof by administering a dairy-derived peptide to the subject, particularly a β-lactoglubulin-derived peptide (β-Lg peptide). According to one aspect, the modulation of the immune system is the modulation of a Th1 response. According to another aspect, the modulation of the immune system is the modulation of a Th2 response. | 2009-12-03 |
| 20090297546 | AVIAN-DERIVED ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HUMAN HMGB1, IMMUNOLOGICAL DETERMINATION METHOD FOR HUMAN HMGB1, AND IMMUNOLOGICAL DETERMINATION REAGENT FOR HUMAN HMGB1 - An object of the present invention is to provide an anti-human HMGB1 antibody having high capability of binding to human high mobility group box protein- | 2009-12-03 |
| 20090297547 | PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0938 PROTEIN - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a | 2009-12-03 |
| 20090297548 | IMMUNOGENIC COMPOSITIONS COMPRISING ANTHRAX SPORE-ASSOCIATED PROTEINS - Compositions and methods for treating a | 2009-12-03 |
| 20090297549 | CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES - The invention relates to polynucleotides which are conserved or specific to one or more species of | 2009-12-03 |
| 20090297550 | Chloroplast-derived human vaccine antigens against malaria - Disclosed is a method of making a malaria vaccine, the method comprising stably transforming a plant by inserting into its plastid genome a nucleic acid sequence encoding and operable to constitutively express a malaria antigenic polypeptide selected from AMA-1, MSP-1 or both; harvesting the stably transformed plant in whole or in part; purifying the expressed malaria antigenic polypeptide from the harvested plant; and packaging the purified antigenic polypeptide under sterile conditions in an amount for a predetermined dosage. Also disclosed is an oral vaccine effective in raising malaria antibodies in a susceptible host, the vaccine comprising leaf material from an edible plant containing plastids stably transformed to constitutively express a fusion polypeptide consisting essentially of cholera toxin B subunit and a malaria antigenic polypeptide selected from AMA-1, MSP-1 or both. | 2009-12-03 |
| 20090297551 | ADJUVANT - This invention relates to a novel adjuvant comprising a transfection reagent, and to uses of this adjuvant. In particular, the adjuvant may be used in compositions for eliciting an immune response and in vaccines. | 2009-12-03 |
| 20090297552 | FLAGELLIN POLYPEPTIDE VACCINES - Vaccines that comprise or generate immunomodulatory flagellin polypeptides able to stimulate an innate immune response intracellularly and extracellularly employ viruses, bacteria or parasitic cells that contain expression systems for such polypeptides, as well as fusion proteins that contain antigens and/or cell penetrating peptides along with the immunomodulatory peptide. | 2009-12-03 |
| 20090297553 | Regimens for Immunisation With Meningococcal Conjugates - Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months. | 2009-12-03 |
| 20090297554 | Multi Plasmid System For The Production Of Influenza Virus - Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. | 2009-12-03 |
| 20090297555 | RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS - The present invention relates to recombinant HCMV (human cytomegalovirus) expressing a pp65 polypeptide or fragment thereof fused to a heterologous or non-native polypeptide, in particular immunogenic and/or antigenic polypeptides. In particular, the heterologous gene products include antigenic or immunogenic polypeptides from a variety of pathogens, cellular genes, tumor antigens, and viruses. The recombinant viruses may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens. | 2009-12-03 |
| 20090297556 | Salmonella Based Oral Vaccines for Anthrax - A vaccine for the prevention of anthrax, including a live, attenuated | 2009-12-03 |
| 20090297557 | HUMAN PARVOVIRUS: BOCAVIRUS - Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Bocavirus-2, and variants thereof. Also provided are methods of detecting the Bocavirus-2 and diagnosing Bocavirus-2 infection, methods of treating or preventing Bocavirus-2 infection, and methods for identifying anti-Bocavirus-2 compounds. | 2009-12-03 |
| 20090297558 | Inactivated Influenza Virus Compositions - The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza. | 2009-12-03 |
| 20090297559 | USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS - The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa. | 2009-12-03 |
| 20090297560 | Oral vaccine for Borrelia - The present invention relates to vaccines for control of | 2009-12-03 |
| 20090297561 | Method for vaccination of poultry by bacteriophage lysate bacterin - The invention provides methods of generating phage lysate bacterins, as well as phage lysate bacterin compositions. The invention further encompasses methods of vaccination comprising administering phage lysate bacterin to an animal in need thereof. The invention further encompasses methods of reducing infection or colonization of poultry or poultry eggs using phage bacterin lysates. | 2009-12-03 |
| 20090297562 | PHARMACEUTICAL COMPOSITIONS AND METHODS TO VACCINATE AGAINST DISSEMINATED CANDIDIASIS AND OTHER INFECTIOUS AGENTS - The invention provides a vaccine including an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated Als protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. | 2009-12-03 |
| 20090297563 | Diagnosis And Treatment of Immune-Related Diseases - The present invention relates to association of one or more polymorphisms located in the human SFRS8, CD83, SLAMF1, CD86, HRH1, IL2, TLR7, TLR8 and TLR10 genes to the occurrence of allergic diseases such as rhinitis, asthma, and atopic dermatitis, auto-immune diseases, infectious diseases, and graft/host incompatibilities. The invention relates both to methods for diagnosing a predisposition to said diseases, classifying said diseases and to methods and compositions for treating subjects with said diseases. Furthermore the invention relates to screens for identifying compounds effective in treating said diseases. The invention describes specific single nucleotide polymorphisms the presence of which in the genome of an individual is strongly associated with the predisposition of said individual to an immune related disease. | 2009-12-03 |
| 20090297564 | Use of a Liquid Allergy Vaccine Formulation for Oromucosal Administration - The present invention relates to the use of an allergen for the manufacture of a liquid vaccine formulation for preventing or treating allergy in a subject by oromucosal administration in a dosage regimen comprising no up-dosing. | 2009-12-03 |
| 20090297565 | METHOD AND DEVICE FOR PRODUCING VERY FINE PARTICLES AND COATING SUCH PARTICLES - Disclosed are methods and devices for producing very fine particles which are then coated with protective polymers in another step of the process. The particles are produced using a method in which a liquid flow comprising a particle-free liquid 1 that contains the active substance in a dissolved form is combined with a second liquid flow comprising a liquid 2 in a high-energy zone or no sooner than two seconds before reaching the high-energy zone. Said two liquids can be mixed with each other while the active substance dissolved in liquid 1 is insoluble or more difficult to dissolve in liquid 2 than in liquid 1 and settles in the form of particles in the high-energy zone or within a maximum of 2 seconds before reaching the high-energy zone when the two liquids are mixed. The obtained particles are introduced into an aqueous outer phase which contains the coating materials in a dissolved form and are then subjected to a drying step such that said materials settle on the particles as a closed coating. The coated particles are protected from damaging influences and are provided with modified release kinetics compared to uncoated particles. | 2009-12-03 |
| 20090297566 | Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions - The present invention provides stabilized thyroid hormone pharmaceutical compositions, and methods of packaging and storing thyroid hormone pharmaceutical compositions, such as levothyroxine (T | 2009-12-03 |
